Search
Etodolac
go.drugbank.com/drugs/DB00749ApprovedInvestigationalVet approvedEtodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of sig...
Flucytosine
go.drugbank.com/drugs/DB01099ApprovedInvestigationalA fluorinated cytosine analog that is used as an antifungal agent.
Glucosamine
go.drugbank.com/drugs/DB01296ApprovedGlucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance … [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter.
Products: GLUCOSAMINA MYLAN GENERICS, GLUCOSAMINA SOLFATO DOC GENERICIFibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalFibrinogen concentrate (human) is a hematological agent. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. It is a soluble plasma glycoprotein with a molecular weight of about 3...
Benzophenone
go.drugbank.com/drugs/DB01878ApprovedSubstituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.
Pentolinium
go.drugbank.com/drugs/DB01090ApprovedPentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Ibandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Mixtures: ASCENDRA TRIO 500CA+1000D3Products: ACIDO IBANDRONICO DOC GENERICIFB-101
go.drugbank.com/drugs/DB17956InvestigationalDeveloped by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalAs of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … [L38429] Tisotumab vedotin-tftv is marketed under the trade name Tivdak as an intravenous injection. On April 29, 2024, tisotumab vedotin was granted full FDA approval.